您所在位置:首页 > 人才队伍 > 研究组长
黄永焯

姓名:黄永焯 性别: 职称:研究员 学历:博士 电话:0760-85286866-8203 电子邮件:yzhuang@zidd.ac.cn 职务:课题组长 通讯地址:广东省中山翠亨新区中瑞(欧)工业园健康医药示范区

  • 个人简历

    教育经历
    2002.09 - 2005.07 浙江大学药学院
    1999.09 - 2002.07 广州中医药大学临床药理研究所
    1995.09 - 1999.07 广州中医药大学中药学院
    工作经历
    2020.07 - 至今   中科中山药物创新研究院
    2010.07 - 至今   中国科学院上海药物研究所
    2008.09 - 2010.06 University of Michigan, Senior Research Fellow
    2005.11 - 2008.08 University of Michigan, Research Fellow

    2011年入选中科院BR计划(结题获优秀),上海市浦江人才计划,科技部中青年科技创新领军人才,中科院特聘研究员计划,获得中国药学院-赛诺菲青年生物药物奖,获得国家自然科学基金优青、杰青。现任International Journal of Pharmaceutics 亚洲区编辑,Nano Letters, Journal of Controlled Release, Acta Pharmaceutica Sinica B 编委;药学学报、中药新药与临床药理、中国现代应用药学、药学进展编委。任中国药学会药剂学专业委员会委员,中国药学会纳米药物专业委员会委员。

  • 研究领域

    1.靶向给药系统;
    2.透皮给药;
    3.难溶性药物给药技术。

  • 研究成果

    采用先进药物递送技术提高体内药物输送效率,并对其转运特性及机制进行了研究,着重考察了在耐药肿瘤治疗的应用。多药耐药已成为了肿瘤治疗最大的障碍之一,本课题组的研究聚焦于耐药肿瘤治疗的这一关键科学问题,通过靶向调控肿瘤微环境的递药策略及治疗策略,致力于研究肿瘤相关巨噬细胞调控与肿瘤耐药(化疗耐药、分子靶向治疗耐药及免疫耐药)。

  • 代表性论著(*:通讯作者)

    1.He Y#, Fang YF#, Zhang M, Zhao YG, Tu B, Shi MJ, Muhitdinov B, Asrorov A, Xu Q, Huang YZ*. Remodeling “Cold” Tumor Immune Microenvironment via Epigenetic-Based Therapy Using Targeted Liposomes with In Situ Formed Albumin Corona. Acta Pharmaceutica Sinica B 2021, impress

    2.Wu CH#, Xu Q#, Wang HY*, Zeng JX, Tu B, Zhao PF, Shi MJ, Qiu H*, Huang YZ*. Neutralization of SARS-CoV-2 Pseudovirus Using ACE2-Engineered Extracellular Vesicles. Acta Pharmaceutica Sinica B 2021, in press

    3.Ou AT, Zhang JX, Fang YF, Wang R, Tang XP, Zhao PF, Zhao YG, Zhang M, Huang YZ*. Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. Acta Pharmacologica Sinica, 2021, in press

    4.Wu AH, Chen YZ, Wang HR, Chang Y, Zhang M, Zhao P, Tang YS, Xu Q*, Zhu ZZ, Cao Y, Huang YZ*. Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy. Acta Pharmaceutica Sinica B, DOI: 10.1016/j.apsb.2021.06.001

    5.Tang YS, Fan WF, Chen GH, Zhang M, Tang XP, Wang HR, Zhao PF, Xu Q, Wu ZB*, Lin XX, Huang YZ*. Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment. Nano Today 2021, 40: 101244

    6.Zhao PF, Zhang JX, Wu AH, Zhang M, Zhao YG, Tang YS, Wang B, Chen TX, Li F, Zhao Q*, Huang YZ*. Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. Journal of Controlled Release 2021, 329: 1249-1261

    7.Fang YF#, He Y#, Wu CH, Zhang M, Gu ZY, Zhang JX, Liu EG, Xu Q*, Asrorov AM, Huang YZ*. Magnetism-mediated targeting hyperthermia-immunotherapy in “cold” tumor with CSF1R inhibitor. Theranostics 2021, 11(14):6860-6872

    8.Asrorov AM, Gu ZY, Li F, Liu LY, Huang YZ*. Biomimetic camouflage delivery strategies for cancer therapy. Nanoscale, 2021, 13(19): 8693-8706

    9.Zhao PF, Tang XP, Huang YZ*. Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine. View, 2021, 2:20200127 (Back cover)

    10.He ZD, Zhang M, Wang YH, He Y, Wang HR, Chen BF, Tu B, Zhu SQ, Huang YZ*. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacologica Sinica, 2021, 42(9): 1516-1523

    11.Tu B, He Y, Chen BF, Wang YH, Gao YR, Shi MJ, Liu TB, Asrorov, AM, Huang YZ*. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomaterials Science, 2020, 8(24): 7166-7176

    12.Zhen ZN, Zhang JX, Jiang JZ, He Y, Zhang WY, Mo XP, Kang XJ, Xu Q*, Wang B, Huang YZ*. Remodeling Tumor Immune Microenvironment (TIME) for Glioma Therapy Using Multi-Targeting Liposomal Codelivery. Journal for ImmunoTherapy of Cancer, 2020, 8(2): e000207

    13.Zhao YG, Yang YT, Zhang JX, Wang R, Cheng BY, Kalambhe D, Wang YS, Gu ZY, Chen DY*, Wang B*, Huang YZ*. Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharmaceutica Sinica B, 2020, 10(10): 1966-1976

    14.Chen BF, Gao A, Tu B, Wang YH, Yu XL, Wang YS, Xiu YF, Wang B, Wan YK, Huang YZ* Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials, 2020, 255:120187

    15.Yin WM, Zhao YG, Kang XJ, Zhao PF, Fu X, Mo XP, Wang YH, Wan YK, Huang YZ*. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation. Theranostics, 2020, 10(14): 6122

    16.Wang HR, Huang YZ*. Combination Therapy Based on Nano Codelivery for Overcoming Cancer Drug Resistance. Medicine in Drug Discovery, 2020, 100024

    17.Chang Y, Jiang J, Chen W, Yang W, Chen L, Chen P, Shen J, Qian S, Zhou T, Wu LF, Hong L, Huang YZ*, Li F*. Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. Applied Materials Today 2020, 18: 100492

    18.Zhang JX, Zhao YG, Hou T, Zeng H, Kalambhe C, Wang B*, Shen X, Huang YZ*. Macrophage-based nanotherapeutic strategies in ulcerative colitis. Journal of Controlled Release 2020, 320:363 (Back cover)

    19.Tu B, Zhang M*, Liu T, Huang YZ*. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Frontiers in Cell and Developmental Biology 2020, 8: 400

    20.Asrorov AM, Gu Z, Min KA, Shin MC*, Huang YZ* Advances on Tumor-Targeting Delivery of Cytotoxic Proteins. ACS Pharmacology & Translational Science 2020, 3(1): 107

    21.Ouyang X, Wang X, Kraatz HB, Ahmadi S, Gao J, Lv Y, Sun X*, Huang YZ*. A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis. Biomaterials Science 2020, 8: 1160

    22.Zhong HH, Wang HY*, Li J, Huang YZ*. TRAIL-based gene delivery and therapeutic strategies Acta Pharmacologica Sinica, 2019, 40: 1373

    23.Sun XY*, Zeng LH, Huang YZ*. Transcutaneous Delivery of DNA/mRNA for Cancer Therapeutic Vaccination. Journal of Gene Medicine 2019, 21(7): e3089

    24.Wang HR, Tang YS, Fang YF, Zhang M, Wang HY, He ZD, Wang B, Xu Q, and Huang YZ*. Reprogramming Tumor Immune Microenvironment (TIME) and 2 Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. Nano Letters 2019, 19(5):2935

    25.Zhang WY, Kang XJ, Yuan B, Wang HY, Zhang T, Shi MJ, Zheng ZN, Zhang YH, Peng CY, Fan XM, Shen YQ, Huang YZ*. Nano-structural effects on gene transfection: large, botryoid-shaped nanoparticles enhance DNA delivery via macropinocytosis and effective dissociation, Theranostics 2019, 9(6):1580-98

    26.Chang Y, Yao S, Chen YF, Huang JJ, Wu AH, Zhang M, Xu Fan, Li F ang Huang YZ*. Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy. Nanoscale 2019, 11: 611-621.

    27.Jin HY, He Y, Zhao PF, Hu Y*, Tao J, Chen J, Huang YZ*. Targeting lipid metabolism to overcome EMTassociated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 2019, 9(1): 265-278 (Front cover).

    28.Chen W, Yang W, Chen PY, Huang YZ*, Feng L*. Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers. ACS Appl. Mater. Interfaces 2018, 10(48): 41118-41128

    29.Zhao PF, Wang HY, Wu AH, Rao YF, and Huang YZ*. Roles of Albumin-Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery. Chembiochem 2018, 19(17): 1796-1805.

    30.Yin WM, Yu XL, Kang XJ, Zhao YG, Zhao PF, Jin HY, Fu XH, Wan YK*, Peng CY, and Huang YZ*. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery. Small 2018, 14(47): 1802372.

    31.Mo XP, Zheng ZN, He Y, Zhong HH, Kang XJ, Shi MJ, Liu TB, Jiao Z, Huang YZ*. Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. Journal of Controlled Release 2018, 287: 12-23.

    32.Kang XJ, Zheng ZN, Liu ZH, Wang HY, Zhao YG, Zhang WY, Shi MJ, He Y, Cao Y, Xu Q*, Peng CY, Huang YZ*. Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis. Molecular Pharmaceutics 2018, 15, 1618−1626.

    33.Zhao PF, Wang YH, Kang XJ, Wu AH, Yin WM, Tang YS, Wang JY, Zhang M, Duan Y and Huang YZ*. Dual-Targeting Biomimetic Delivery for Antiglioma via Remodeling Tumor Microenvironment and Directing Macrophage-Mediated Immunotherapy. Chemical Science 2018, 2674–2689 (Back front cover)

    34.Xu F, Zhong HH, Chang Y, Li DD, Jin HY, Zhang M, Wang HY, Jiang C, Shen YQ, Huang YZ*. Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuliresponsive self-assembling nanocomposites. Biomaterials 2018, 158:56-73

    35.Li DD, Zhang M, Xu F, Chen YZ, Chen BF, Chang Y, Zhong HH, Jin HY, Huang YZ*. Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation. Acta Pharmaceutica Sinica B 2018, 8(1): 74-84 (Back front cover)

    36.Chen YZ, Zhang M, Min KA, Wang HY, Shin MC*, Li F, Yang V, Huang YZ*. Improved Protein Toxin Delivery Based on ATTEMPTS Systems. Current Drug Targets 2018, 19(4): 380-392

    37.He Y, Li F*, Huang YZ*. Smart Cell-Penetrating Peptide-Based Techniques for Intracellular Delivery of Therapeutic Macromolecules. Adv Protein Chem Struct Biol. 2018;112:183-220

    38.Peng HG, Chen BF, Huang W, Tang YB, Jiang YF, Zhang WY, Huang YZ*. Reprogramming Tumor-Associated Macrophages to Reverse EGFR(T790M) Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. Nano Letters 2017, 17(12): 7684-90

    39.Zhao PF, Yin WM, Wu AH, Tang YS, Wang JY, Pan ZZ, Lin TT, Zhang M, Chen BF, Duan Y, Huang YZ*. Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy. Advanced Functional Materials 2017, 27(44): 1700403 (Front Cover)

    40.Chen YZ, Zhang M, Jin HY, Li DD, Xu F, Wu AH, Wang JY, Huang YZ*. Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery. Theranostics 2017, 7(14): 3489-503

    41.Xu JJ, Xu BH, Tao J, Yang YX, Hu Y*, Huang YZ*. Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel. Small 2017, 13(28): 1700666

    42.Chen YZ, Zhang M, Jin HY, Tang YS, Wang HY, Xu Q, Li YP, Li F, Huang YZ*. Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature. Biomaterials 2017, 116: 57-68

    43.Tang YS, Liang JM, Wu AH, Chen YZ, Zhao PF, Lin TT, Zhang M, Xu Q*, Wang JM*, Huang YZ*. Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis. ACS Applied Materials & Interfaces 2017, 9(32): 26648-64

    44.Pan ZZ, Kang XJ, Zeng YE, Zhang WY, Peng HG, Wang JY, Huang W, Wang HY*, Shen YQ, Huang YZ*. A mannosylated PEI–CPP hybrid for TRAIL gene targeting delivery for colorectal cancer therapy. Polymer Chemistry 2017, 8(35): 5275-85 (Front Cover)

    45.Chen YZ, Zhang M, Jin HY, Tang YS, Wu AH, Xu Q, Huang YZ*. Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance. Molecular Pharmaceutics 2017, 14(5): 1429-38

    46.Tan J, Wang HY, Xu F, Chen YZ, Zhang M, Peng HG, Sun X*, Shen YQ, Huang YZ*. Poly-γ-glutamic acid-based GGT-targeting and surface camouflage strategy for improving cervical cancer gene therapy. Journal of Materials Chemistry B 2017, 5:1315-1327

    47.Kan XJ, Wang HY, Peng HG, Chen BF, Zhang WY, Wu AH, Xu Q*, Huang YZ*. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacologica Sinica 2017, 38(6): 885-96 (Serving as Co-Guest Editors for the featured issue)

    48.Zhang M, Liu E, Cui Y, Huang YZ*. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biology & Medicine 2017, 14(3): 212-27

    49.Wang HY, Moon C, Shin MC, Wang YP, He HN, Yang V*, Huang YZ*. Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. Nanotheranostics 2017, 1(1): 114-30

    50.Lin TT, Zhao PF, Jiang YF, Tang YS, Jin HY, Pan ZZ, He HN, Yang V, Huang YZ*. Blood–Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. ACS Nano 2016, 10:9999-10012

    51.Cui YN, Zhang M, Zeng F, Jin HY, Xu Q, Huang YZ*. Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Applied Materials & Interfaces 2016, 8: 32159-32169

    52.Lin TT, Liu EG, He HN, Shin MC, Moon C, Yang V*, Huang YZ*. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharmaceutica Sinica B 2016, 6: 352–358 (Back front cover)

    53.Pan ZZ, Wang HY, Zhang M, Lin TT, Zhang WY, Zhao PF, Tang YS, Xiong Y, Zeng YE* and Huang YZ*. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacologica Sinica 2016, 37: 1110–1120 (Editor choice)

    A full publication list is available via Google Scholar. https://scholar.google.com/citations?user=Z-yoe34AAAAJ

    Book Chapter:

    54.Zhang M, Liu EG*, Huang YZ*. Magnetically Responsive Nanomedicine. Chapter 7 in Stimuli-Responsive Nanomedicine © 2020 Jenny Stanford Publishing Pte. Ltd.

    55.Zhao PF, Li F*, Huang YZ*. Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer. Chapter 10 in Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies ©2020 Elsevier

    56.Liu EG, Zhang M, Huang YZ*. Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials. Chapter 1 in Biomedical Nanomaterials.© 2016 Wiley-VCH

    57.Mo XP, Liu EG, Huang YZ*. The intra-brain distribution of brain targeting delivery systems. Chapter in Brain Targeted Drug Delivery System ©2018 Elsevier


    点击展开 ▾